Recombinant adeno-associated virus for muscle directed gene therapy

Nature Medicine

Volumn 3, Issue 3, 1997, Pages 306-312

  Fisher, Krishna J ^a   Jooss, Karin ^a   Alston, James ^a   Yang, Yiping ^a   Haecker, Sarah Ehlen ^a   High, Katherine ^b,c   Pathak, Ravindra ^a   Raper, Steven E ^b   Wilson, James M ^a,d  

^a Institute for Human Gene Therapy   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; GENE THERAPY; GENE TRANSFER; MONKEY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKELETAL MUSCLE; VIRUS RECOMBINANT;

ANIMALS; DEPENDOVIRUS; DNA, RECOMBINANT; DNA, VIRAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; MICE; MICE, TRANSGENIC; MUSCLE, SKELETAL;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; ANIMALIA; MIRIDAE;

EID: 0031058024     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0397-306     Document Type: Article

References (12)

1. Kotin, R.M. Prospects for the use of adeno-associated virus as a vector for human gene therapy. Hum. Gene Ther. 5, 793-801 (1994).
2. Kotin, R. et al. Site-specific integration by adeno-associated virus. Proc. Natl. Acad. Sci. USA 87, 2211-2215 (1990).
3. Samulski, R. et al. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J. 10, 3941-3950 (1991).
4. Berns, K.I. Parvovirus replication. Microbiol. Rev. 54, 316-329 (1990).
5. Samulski, R., Chang, L. & Shenk, T. Helper-free stocks of recombinant adeno-associated viruses: Normal integration does not require viral gene expression. J. Virol. 63, 3822-3828 (1989).
6. Russell, D., Miller, A. & Alexander, I. Adeno-associated virus vectors preferentially transduce cells in S phase. Proc. Natl. Acad. Sci. USA 91, 8915-8919 (1994).
7. Alexander, I.E., Russell, D.W. & Miller, A.D. DNA-damaging agents greatly increase the transduction of nondividing cells by adeno-associated virus vectors. J. Virol. 68, 8282-8287 (1994).
8. Russell, D.W., Alexander, I.E. & Miller, A.D. DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors. Proc. Natl. Acad. Sci. USA 92, 5719-5723 (1995).
9. Fisher, K.J. et al. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J. Virol. 70, 520-532 (1996).
10. Ferrari, F.K., Samulski, T., Shenk, T. & Samulski, R.J. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J. Virol. 70, 3227-3234 (1996).
11. Kumar, S. & Leffak, M. Conserved chromatin structure in c-myc 5′-flanking DNA after viral transduction. J. Mol. Biol. 222, 45-57 (1991).
12. Kaplitt, M.C. et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nature Genet. 8, 148-154 (1994).